Ariosa Dx Prices IPO, Anticipates Net Proceeds of up to $61M | GenomeWeb

NEW YORK (GenomeWeb) – Ariosa Diagnostics has priced its planned initial public offering of 3.5 million shares.

In an amended Form S-1 filed with the US Securities and Exchange Commission on Thursday, the company priced its common shares at a range of $16 to $18 per share. At the $17 midpoint price, the offering would bring in net proceeds of $52.3 million, the San Jose, Calif.-based non-invasive prenatal testing firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.